2230198-02-2
- Product Name：Danuglipron
- Molecular Formula：C31H30FN5O4
- Purity：99%
- Molecular Weight：555.6
Product Details:
CasNo： 2230198-02-2
Molecular Formula： C31H30FN5O4
Buy Reliable Quality Danuglipron,Offer 2230198-02-2 Fast Shipping
- Molecular Formula:C31H30FN5O4
- Molecular Weight:555.6
Danuglipron(Cas 2230198-02-2) Usage
|
Description |
Danuglipron, also known as PF-06882961, is an experimental medication developed by Pfizer as a GLP-1 receptor agonist. GLP-1 agonists work by mimicking the action of the natural hormone GLP-1, which helps regulate blood sugar levels and appetite. Danuglipron is designed to be taken orally in tablet form. |
| Uses |
Danuglipron is being investigated as a potential therapy for diabetes mellitus. As a GLP-1 receptor agonist, it has the potential to improve glycemic control by stimulating insulin secretion and reducing glucagon secretion in response to meals. Additionally, GLP-1 agonists have been shown to promote weight loss, making them particularly beneficial for individuals with type 2 diabetes who are overweight or obese. |
2230198-02-2 Relevant articles
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial
Aditi R. Saxena，Donal N. Gorman，Ryan M. Esquejo，Arthur Bergman，Albert M. Kim
, Nature Medicine 2021/06/01
We then completed a placebo-controlled, randomized, double-blind, multiple ascending-dose phase 1 study (NCT03538743), in which we enrolled 98 patients with T2D on background metformin and randomized them to receive multiple ascending doses of danuglipron or placebo for 28 d, across eight cohorts.
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide1 Receptor
amits，scottw，joaom，davidr，aditir，jayeshc，johnm，alanm，rogerb，davida
Journal of Medicinal Chemistry, 2022
Danuglipronincreased insulin levels in primates but not rodents, which was explainedby receptor mutagensis studies and a cryogenic electron microscopestructure that revealed a binding pocket requiring a primate-specifictryptophan 33 residue. Oral administration of danuglipron to healthyhumans produced dose-proportional increases in systemic exposure (NCT03309241).
Relevant Products
-
PralsetinibCAS：2097132-94-8
-
Diatrizoic AcidCAS：50978-11-5
-
Heparin SodiumCAS：9041-08-1
